Clinical Trial Update: A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD [Phase 2]

View source ↗

Summary

Phase 2 trial update for a delayed and extended-release formulation of dextroamphetamine sulfate (HLD100) in children with ADHD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Dextroamphetamine sulfate (HLD100) (dextroamphetamine sulfate)

Snippet

Sponsor: Ironshore Pharmaceuticals and Development, Inc | Conditions: Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Status: COMPLETED